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Summary One hundred and seventeen patients with cerebral glioma (Kernohan grades III and IV) were
treated with adjuvant chemotherapy using procarbazine (PCB), CCNU and vincristine (VCR) following
whole head irradiation. Cell cultures were prepared from 40 patients in this series and their sensitivity to each
cytotoxic drug was assessed in a mictotitration assay with 35 S-methionine incorporation as the end point.
Twenty-two of forty (55%) patients responded to PCB and/or CCNU in vitro, and sensitivity to these drugs
was linked with increased RFI, whilst sensitivity to VCR was not. The RFI of patients who had responded to
PCB or CCNU in vitro was significantly longer than the RFI of patients whose tumours failed to respond in
vitro or patients who had not been tested. There was no difference in sex ratio, extent of operation, radiation
dose and degree of steroid cover between responders, non-responders and untested groups. Grade III tumours
tended to be more sensitive in vitro than grade IV tumours. The age of patients also influenced in vitro
chemosensitivity. Patients with chemosensitive tumours in vitro tended to be younger than patients with
insensitive tumours in vitro. Further statistical analysis, taking into account these prognostic factors, indicated
an association between chemosensitivity in vitro and RFI.
Malignant cerebral gliomas represent a formidable
clinical challenge despite over 50 years of intensive
clinical and experimental investigation. While
radiotherapy and chemotherapy both prolong
useful life (Walker & Gehan, 1976; Bloom, 1982)
the long-term prognosis for patients with this
disease remains consistently poor.
There is widespread morphological variation in
gliomas of similar clinical malignancy (Russell &
Rubinstein, 1977) and recent evidence suggests that
this variability may extend to characteristics other
than morphology (Shapiro et al., 1981; Bigner et
al., 1981; Bradley et al., 1978; Bullard et al., 1981a).
It is possible that sensitivity to cytotoxic drugs
varies between individual tumours (Barranco et al.,
1973; Kimball & Brattain, 1980) and that this is an
explanation for the clinical observation of the wide
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variation in response to chemotherapy amongst
patients with otherwise similar tumours. Attempts
to investigate this problem in the laboratory using a
variety of in vitro and in vivo techniques (Gazso &
Afra, 1969; Mealey et al., 1974; Kornblith &
Szypko, 1978; Easty & Wylie, 1963; Saez et al.,
1977; Rosenblum et al., 1978, 1983; Shapiro et al.,
1979; Bullard et al., 1981b) have all demonstrated
that human gliomas display considerable variation
in chemosensitivity. In this report we present data
produced with a rapid 35 S-methionine uptake assay
(Darling & Thomas, 1983; Freshney & Dendy,
,1983) where the end-point has been measured by
scintillation autofluorography (Thomas et al., 1979;
Morgan et al., 1983) which permits a rapid,
objective comparison of in vitro and clinical data.
Materials and methods
Cell culture and chemosensitivity assay
Biopsy samples were taken at operation for routine
diagnostic neuropathological examination. Histo-
logy was reported by consultant neuropathologists
at The National Hospitals, Queen Square or Maida
Vale as either grade III or grade IV malignant
glioma. Of 48 biopsies submitted for tissue culture,
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40 (83%) were evaluable for chemosensitivity. Two
(4%) became contaminated and 6 (12.5%) cases
failed to grow in culture. Samples were collected in
Ham's F-10 culture medium supplemented with
100 uml- 1 penicillin, 100jigml- 1 streptomycin and
buffered with 20mM HEPES. Cell culture and the
chemosensitivity assay have both been described in
detail previously (Thomas et al., 1979; Morgan et
al., 1983). Briefly, cells at passage level 1 or 2 were
diluted to 1-5 x I05cellsml - inoculated onto 96-
well microtitration plates (1-5 xl04 cells/well) and
incubated at 37°C for 24-72 h. Stock drug solutions
were made up as follows: VCR (Oncovin, Eli Lilly)
00jMgml-1; PCB (Natulan, Roche) 500Mgml - in
Ham's F-10 medium and CCNU (Lundbeck)
100jugml-I in absolute ethyl alcohol, and
subsequently stored at -80°C. Drug solutions were
all diluted in Ham's F-10 plus 10% foetal calf
serum, with 50uml- penicillin, 50 ,ugml-1
streptomycin and buffered with 20mM HEPES. At
the time of testing, 0.2 ml of each drug dilution was
added to the appropriate wells and renewed 24 and
48 h later to give a total exposure time of 72h. The
concentration ranges of drugs used in this study has
been published together with their relationship to
the in vivo concentrations attainable (Morgan et al.,
1983). Finally, the drugs were removed and each
well gently washed and filled with 0.2ml of
fresh growth medium. After 3-5 days recovery
period, 0.1 ml of 2pCiml-I of 35 S-methionine was
added to each well, and incubated for 4-18h. The
plates were then washed in Hanks' buffered saline,
fixed in methanol, extracted in trichloroacetic acid,
washed in tap water and dried in methanol.
Toluene-based scintillation fluid (50pl) was added
to each well and the plates were dried by
centrifugation. A sheet of X-ray film was then
placed under each plate and exposed for between
24h and 2 weeks. Each column of the developed
negative was scanned with a densitometer and the
ID50 (the dose of the drug which inhibited protein
synthesis by 50%) was determined from the
densitometer traces (Thomas et al., 1979).
Previous studies with HeLa cells (Freshney et at.,
1975) have shown that prolonged exposure to drugs
followed by recovery were necessary to obtain
stable ID50 values for most drugs, especially phase
specific agents. Therefore, in order to minimise
internal variation in the assay, cultures were
sampled after 3-5 days recovery but before density
limitation of growth occurred (Morgan et al., 1983).
At this point, the ID50 measured by clonogenicity
and microtitration assay correlate well (Morgan et
al., 1983). The ID50 of each glioma cell culture was
determined and compared to a panel of 123
cultures derived from tumours of the same
histology that had been assayed for chemo-
sensitivity to PCB, CCNU and VCR in this
laboratory using the same assay. Sensitivity was
defined as an ID50 below the median ID50 of the
panel of cultures. If the ID50 was above the median
for the group then the culture was designated a
non-responder.
Patients
One hundred and seventeen patients (see Table II)
with histologically verified malignant gliomas were
treated post operatively with a combination of
radiotherapy and chemotherapy. Radiation was
administered either to the whole brain, or to a
complete hemisphere with appropriate overlap to
include possible extension into the opposite
hemisphere. The tumour minimum dose was 40-
60 Gy. Steroid therapy with dexamethasone or
betamethasone was used as necessary to control
raised intracranial pressure, but at the lowest
maintenance dose consistent with good medical
management and stopped, in most cases, as soon as
radiation treatment had been completed. It was
only reintroduced when signs and symptoms were
indicative of tumour recurrence. From 2-6 weeks
after the completion of radiation therapy, patients
began chemotherapy, on an outpatient basis,
consisting of VCR, 1.4 mgm-2 as a single dose,
CCNU, 80 mgm-2 as a single dose, orally, and
PCB, orally, 100mgm-2 per day over 10 days.
Patients were reviewed clinically and haema-
tologically every 6 weeks on an outpatient basis.
Patients were treated for 12 cycles over an 18-
month period. Computerized tomography (CT) was
performed routinely approximately every 3 months
during active therapy and every 6 months following
its completion. The time from surgery until disease
progression was termed the relapse free interval
(RFI). Disease progression was defined as a marked
deterioration in clinical status, which was in most,
but not all cases, accompanied by a worsening in
the CT scan. The criteria for deterioration used in
this study were similar to those described by Levin
et al. (1977) except that electroencephalographic
recordings and radionuclide scanning were not
routinely performed. Relapse free interval was
chosen in this study rather than survival as
extensive use of high dose glucocorticoids to
control cerebral oedema can prolong survival
considerably even in the face of obvious tumour
recurrence. To be included in this study, all patients
must have received a full course of radiotherapy
and at least one course of chemotherapy. Patients
were selected for the study purely on clinical
grounds and it was not necessary for a tissue
culture sample to have been taken or a
chemosensitivity assay to have been carried out forASSAY OF ANTI-CANCER DRUGS IN VITRO 527
a patient to receive chemotherapy. All clinical/in
vitro correlations were carried out retrospectively,
and no attempt was made to influence chemo-
therapy using the results of the assay.
Results
Each patient whose cells were assayed was
designated a responder or non-responder to a
particular drug on the criteria described in the
methods section. 14/40 (35%) of patients responded
in vitro to CCNU, 17/40 (42%) of patients
responded to PCB and 16/40 (40%) of patients
responded to VCR. The length of relapse free
interval was compared for those patients who were
responders to a particular drug and those who were
not. The comparison of relapse free intervals were
based on the Mantel-Cox test (Mantel, 1966) for
the comparison of censored survival times and were
computed using Biomedical Data Program (BMDP)
1L. Table I shows the median relapse free intervals
and the quartiles of patients who had sensitive or
insensitive cultures in vitro for each of the 3 drugs
(linear smoothing was used to estimate the
percentiles, Miller, 1981). The differences in RFIs
between the PCB and CCNU responders and non-
responders in vitro were significant (P=0.02 and
P=0.01 respectively). The differences between the
RFIs in the case of responders or non-responders
to vincristine were not significantly different
(P=0.5). A Cox regression model was fitted (using
BMDP 2L) to look at the combined effects of
sensitivity to each drug on RFI. This confirmed
that only sensitivity to PCB and CCNU was
associated with increased RFI.
In vitro chemosensitivity to either PCB or to
CCNU was related to RFI while in vitro sensitivity
to VCR was not. Glioma patients who had
undergone chemotherapy were divided into 3
groups. The first group consisted of 22 responders
in vitro to either PCB or CCNU or to both (Group
A). The second group consisted of 18 patients who
did not respond to either of these drugs in vitro
(Group B). The third group comprised 77 patients
who had not been tested for chemosensitivity
(Group C). Figure 1 shows the Kaplan-Meier
survival plots (Kaplan & Meier, 1958) for the
relapse-free intervals of these groups. The
chemosensitive group (A) remained relapse-free for
longer than the non-chemosensitive group B
(Mantel-Cox test, P<0.0001). The RFIs of those
patients whose cells had been tested in vitro (A+B)
were compared with the RFIs for the untested
group, C, and no significant difference was found
(P=0.28).
To ascertain whether the improved RFI in the
chemosensitive group could be explained as a
function of variation in other prognostic factors, a
comparison was made between the groups on a
number of possible prognostic factors (Table II).
Sex, type or extent of operation, amount of
radiation, steroids and tumour site were not signi-
ficantly different in the 3 groups. There were however
differences in age and grade. The untested group
(C) were older than the tested group (A+B) and
patients who responded in vitro to either CCNU or
PCB (A) tended to be younger than those patients
who did not respond (B), although this difference
did not reach statistical significance. Although there
was no difference in the proportion of grade III
and grade IV tumours between the tested groups
(A+B) and the untested groups (C), there were
fewer 'grade III tumours in the non-chemosensitive
group (B) than in the chemosensitive group (A):
16/22 (73%) sensitive tumours were grade III, but
only 6/22 (27%) sensitive tumours were grade IV.
Conversely, only 4/18 (22%) resistant tumours were
grade III whilst 14/18 (78%) of these tumours were
grade IV.
Further tests were done to see, in the whole
sample, the effect of each of the prognostic factors
on RFI (Table III). Age, grade and site of tumour
were each associated with RFI. Patients with
parietal tumours had shorter RFIs. However,
within group C (the untested patients) there was no
significant difference in RFI between patients with
tumours at different sites. The proportion of
patients with parietal tumours was similar in group
Table I Median relapse free intervals of patients with sensitive and insensitive cell cultures
Median relapsefree intervals (d)
Quartiles CCNU VCR PCB
Non-chemosensitive in vitro 75 178 185 164
median 253 331 233
25 537 527 374
Chemosensitive in vitro 75 332 212 387
median 857 539 609
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Figure 1 Kaplan-Meier survival plots of the relapse free intervals of patients with malignant gliomas who
had been treated with the PCV protocol and were sensitive to PCB and/or CCNU in vitro (Group A), those
who were insensitive to either of these drugs (Group B) and those patients who had not been tested in vitro
(Group C).
Table II Characteristics of patients in the chemosensitive, not chemosensitive and not tested groups
Comparison of Comparison of
Untestedfor tested vs not chemosensitive vs
Testedfor chemosensitivity chemosensitivity testedgroups not chemosensitive
Sensitive Insensitive (Group A +B vs
(group A) (group B) (Group C) group C) (Group A vs group B)
(t-test)
Sample size 22 18 77 P= P=
Age at diagnosis mean 42.9 49.4 51.7 0.019 0.1408
s.d. 12.1 15.2 12.0
Percentage ofgroups (X2-test)
Sex Male 55 78 61 0.82 0.23
Female 45 22 39
Histology Grade III 73 22 40 0.42 0.0042
Grade IV 27 78 60
Tumour site Frontal 50 25 39 0.78 0.07
Temporal 35 25 25
Parietal 15 50 36
Operation Partial 68 56 62 0.98 0.62
Lobectomy 32 44 38
Radiation 0-4999 cGy 74 67 76 0.76 0.98
5000+cGy 26 33 24
Steroids Preoperative 59 47 53 0.91 0.67
Pre & post op. 41 53 47
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C and those patients who had been tested (groups
A and B). However, amongst those tested a higher
proportion of parietal tumours were not sensitive in
vitro.
For groups A and B, Cox's proportional hazard
model (PHM) (Cox, 1972) was fitted using a
forward stepwise procedure and including in the
model, age, grade, site of tumour, chemosensitivity
and including all interactions up to the third order.
The final model showed that when all other factors
were taken into account chemosensitivity was still
related to longer RFI.
To check that the similarity in RFI in the tested
and untested groups was not because an actual
difference was masked by variations in age, grade
or site, a Cox PHM was fitted including these
factors. When the effect of age, grade and site were
taken into account there was still no difference in
RFI between the tested (A+B) and the untested
(C) groups.
Discussion
The triple agent regimen of PCB, CCNU and VCR
has evolved from initial studies by Gutin et al.
(1975) and Shapiro & Young (1976) who combined
three agents which had been reported as modestly
successful single agents for the treatment of glioma.
All three agents are capable of passing the blood-
brain barrier and therefore might be expected to
pass not only into the body of the tumour but also
into the tumour periphery with its infiltrating edge.
Experimental evidence (Rosenblum et al., 1976)
suggests that administering cycle specific agents
such as vincristine after treatment with CCNU and
PCB might enhance maximum cell kill during a
period when tumour cells should be rapidly
proliferating.
From our study we have demonstrated that
patients do not respond to these agents in the same
way. It is possible to divide patients into two
groups, those whose tumours respond to PCB or
CCNU in vitro and those whose tumours do not.
Morphologically similar tumours do not always
uniformly respond to single therapeutic agents.
Usually this is ascribed to vague factors such as
host-tumour interaction or differences in regional
drug delivery. Recent experimental work, has,
however, strongly suggested that the intrinsic
variation in chemosensitivity among individual
tumours may be one factor which is responsible for
these patterns of response. Detailed in vitro studies
(Darling & Thomas, in preparation) indicate that
glioma cell cultures demonstrate considerable
heterogeneity in response to not only PCB, CCNU
and VCR but also to other agents such as
adriamycin, VP 16-213, AZQ, bleomycin and 5-FU.
Shapiro et al. (1981) and Yung et al. (1982) have
demonstrated that clones from a single glioma
biopsy display differing chemosensitivities in vitro.
Kornblith and colleagues (1978, 1981) have
demonstrated considerable variation in the
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study 5/14 patients were insensitive to BCNU and
none of these patients responded clinically to the
drug. The remaining 9 patients did respond in vitro,
but only 6 of them demonstrated clinical response.
Using a cloning assay, Rosenblum and colleagues
(1981, 1983) have found similar variation in in vitro
chemosensitivity to BCNU. From a group of 15
patients, 8 were insensitive to BCNU in vitro and 7
were sensitive. As in Kornblith's study all patients
who failed to respond in vitro also failed to respond
clinically, and only 3 of the sensitive patients
responded to BCNU clinically. In our study 22/40
(55%) of patients were sensitive to either PCB or
CCNU and 18/40 patients failed to respond to
these drugs. It is also apparent that patients who
had tumours sensitive to PCB and/or CCNU in
vitro had significantly longer RFIs than those
patients who did not respond to either of these
drugs, or who were not tested in vitro. Response to
VCR in vitro did not influence RFI.
The apparent ineffectiveness of vincristine in
prolonging relapse free interval is rather unexpected
in light of a number of reports indicating its modest
effect as a single agent (Edwards et al., 1980).
Vincristine does appear to be particularly effective
against rapidly growing intracranial tumours such
as medulloblastomas (Crafts et al., 1978). In
malignant gliomas which have relatively small
growth fractions (often < 10%, Steel, 1980)
vincristine may well be less effective than cycle non-
specific drugs like nitrosoureas and procarbazine.
As the chemosensitivity assay uses exponentially
dividing cells in situ sensitivity may be over-
predicted because of the relative insensitivity on
non-cycling cells in situ. As CCNU and
procarbazine are not restricted in their effectiveness
by cell cycle constraints the in situ effectiveness of
these drugs will be demonstrable in either cycling or
non-cycling cells.
It may be that vincristine cannot penetrate into
the actively growing periphery of the tumour
because of a partially intact blood-brain barrier.
Evidence from animal experiments using intra-
cranial tumour models indicates that the brain
adjacent to the tumour (BAT) is less permeable to
hydrophilic molecules than normal brain while
remaining freely permeable to lipophilic drugs
(Levin et al., 1975). This might indicate that vin-
cristine cannot attain sufficiently high concen-
trations in situ to be effective.
It is unlikely that the reason for the apparent
ineffectiveness of vincristine is due to a rapid
overgrowth of resistant cells or a rapid increase in
de novo resistant cells as our experiments with
glioma cell cultures indicate that cells treated with
vincristine remain sensitive to this drug throughout
a recovery period in fresh growth medium while
cultures recover rapidly from treatment with
procarbazine and CCNU.
Histological grade did seem to effect in vitro
chemosensitivity. Cultures prepared from grade III
tumours were more likely to respond to PCB or
CCNU than cultures prepared from grade IV
tumours. Although grade III tumours are known to
be less aggressive in their clinical history than the
more malignant grade IV tumours, less is known
about therapeutic differences between these groups
of tumours. Bloom (1982) has reported that
clinically grade III astrocytomas tend to be more
sensitive to treatment with nitrosoureas than grade
IV astrocytomas and Levin et al. (1980) has shown
that glioblastoma multiforme is less sensitive to
treatment with PCB, CCNU and VCR than
gliomas of lower grades of malignancy. In vitro,
there is some evidence that cultures from grade III
tumours are more sensitive to BCNU than cultures
derived from grade IV tumours (Kornblith et al.,
1981). The effect of patient age on in vitro
chemosensitivity has already been examined by
Rosenblum et al. (1982) who found an inverse
correlation between sensitivity to BCNU in vitro
and the patients age. Patients with sensitive cells
tended to be younger than those patients with
resistant cells. From our data it is also apparent
that within the tested groups (A+B), fewer parietal
tumours are sensitive in vitro (Table II), and this
results in an overall poorer prognosis for patients
with parietal tumours in the group as a whole. A
detailed examination of the Brain Tumor Study
Group data has failed to confirm that patients with
parietal tumours have a worse prognosis than
patients with tumours in other locations (Byar et
al., 1983).
The association between in vitro chemosensitivity
and RFI demonstrated in this study is in
accordance with studies which have shown a
correlation between in vitro drug sensitivity and
survival of patients with ovarian cancer (Alberts,
1981) and multiple myeloma (Durie et al., 1983). In
a study of patients with relapsed ovarian cancer,
Alberts (1981) has shown that those patients treated
with drugs to which they were sensitive in the assay
had significantly longer survival times than those
patients who were either resistant in the assay or
sensitive but were treated empirically with drugs
not recommended by the assay. In this study, care
was taken to see that these differences in survival
were not simply due to an imbalance of prognostic
factors between groups.
The present study found that length of RFI of
patients with malignant gliomas undergoing
adjuvant chemotherapy is linked with sensitivity
to PCB and CCNU in vitro. Although other
prognostic signs do influence clinical outcome,ASSAY OF ANTI-CANCER DRUGS IN VITRO 531
statistical analysis confirms in vitro chemosensitivity
as a factor in determining relapse free interval. The
next stage is to use this assay to carry out a
prospective trial of chemosensitivity testing for
malignant gliomas.
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